About
Anti-IL-11 Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodySan Diego & Southern California
Team (17)
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
116
By Phase
PHASE2: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06226545Lead Sponsor
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
PHASE2Completed
41 participants
Started: Mar 5, 2024 · Completed: Apr 22, 2025
NCT05331300Lead Sponsor
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
PHASE1/PHASE2Completed
75 participants
Started: Jun 6, 2022 · Completed: Nov 27, 2024
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...